News coverage about Biopharmx Corp (NYSE:BPMX) has trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx Corp earned a news impact score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.6858787171182 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Performance Watch on Healthcare stock: BioPharmX Corporation (BPMX) returned -22.93% down in current week - Street Observer (press release) (streetobserver.com)
- Awesome Oscillator Trending Downward For Biopharmx Corp (BPMX) - FLBC News (flbcnews.com)
- Biopharmx Corp (BPMX) Moves -1.71% - Evergreen Caller (evergreencaller.com)
- Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea - PR Newswire (press release) (prnewswire.com)
- Market Alert: BioPharmX Corporation (BPMX) Becomes Oversold - Voice Of Analysts (analystsbuzz.com)
Shares of Biopharmx Corp (NYSE BPMX) traded up 1.0259% during trading on Friday, reaching $0.3545. The company’s stock had a trading volume of 472,608 shares. The firm’s 50-day moving average is $0.45 and its 200-day moving average is $0.51. The stock’s market capitalization is $26.28 million. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $1.22.
Separately, ValuEngine raised Biopharmx Corp from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 24th.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.
